Laboratory biomarkers or imaging in the diagnostics of rheumatoid arthritis?

Table 1 Diagnostic performance of various anti-citrullinated protein/peptide antibodies assays in rheumatoid arthritis

	Sensitivity (%)	Specificity (%)	Supplementary information	Ref.
CCP	60 to 80	95 to 99	- High significant predictive value	[11, 21]
CCP	60 to 80	95 to 99	- Anti-CCP is a constant feature of RA with 5% changes in disease course	[11, 21]
CCP1	44 to 56	90 to 97	- Peptide from filaggrin protein	[22]
CCP2	60 to 80	96 to 98	- Artificially optimized peptide	[21, 22, 24]
CCP2	60 to 80	96 to 98	- Positive in 20 to 30% of RF-negative RA patients	[21, 22, 24]
CCP3	61 to 83	93 to 98	- Artificially optimized peptide	[22–24]
CCP3	61 to 83	93 to 98	- In early and RF-neg RA patients more prevalent, with higher sensitivity/specificity then CCP2 assays	[22–24]
CCP3.1	54 to 70	94 to 99	- FDA approved for early detection of RA	[23]
MCV	60 to 69	87 to 98	- Similar diagnostic performance as CCP2	[21, 23, 24]
			- Useful in RF-neg, anti-CCP-neg RA patients
			- 10% of CCP-neg and 30% of IgM RF-neg RA patients are MCV positive
			- Simultaneous CCP and MCV assessment improves RA diagnostics to ca. 98%

CCP, cyclic citrullinated peptides; MCV, modified citrullinated vimentin; RA, rheumatoid arthritis; RF, rheumatoid factor.

ISSN: 1741-7015